ERBB2 and breast carcinoma: In our cohort of patients with HER2‐positive breast cancer we observed a median OS of 8.3 months from LM diagnosis, with a significant proportion of patients alive at 1 and 2 years after diagnosis (42% and 21%, respectively), which is considerably longer than reported by most previous studies.